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Abstract  This  is  the  ﬁrst  of  a  two-part  review  that  aims  to  report  the  current  knowledge  of
retinoblastoma  (Rb)  and  its  implications  in  Mexico  (including  the  authors’  experience  at  the
leading Rb  centers),  identify  the  gaps  in  practice,  and  propose  solutions  to  improve  diagnosis,
treatment,  and  patient  uptake.  In  this  ﬁrst  part,  general  knowledge  of  Rb  diagnosis  and  man-
agement is  summarized  with  a  focus  on  the  latest  advances  in  chemotherapy.  A  general  review
of peer-reviewed  literature  of  Rb  was  conducted  on  PubMed.  Key  ﬁndings  were  summarized.
Provided there  is  early  detection  and  referral  of  patients  followed  by  appropriate  conservative
management,  Rb  is  curable.  In  developed  countries,  the  primary  treatment  outcome  is  ocular
salvage with  sight  preservation.  Advanced  chemotherapeutic  options  such  as  intra-arterial  and
intravitreal  chemotherapy  can  now  save  even  the  most  advanced  tumors.
Advances  in  Rb  therapy  are  generally  limited  to  developed  countries.  The  implications  in
Mexico, of  the  ﬁndings  from  this  review  will  be  discussed  in  Part  2,  which  will  be  a  comprehensive
situational  analysis  of  the  state  of  Rb  programming  in  Mexico,  including  a  review  of  current
demographic  data  available  from  hospitals  that  have  Rb  programs  or  treat  Rb.
© 2015  Hospital  Infantil  de  México  Federico  Gómez.  Published  by  Masson  Doyma  México
S.A. This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.
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Retinoblastoma  en  México:  parte  I.  Revisión  del  conocimiento  general  de  la
enfermedad,  diagnóstico  y  tratamiento
Resumen  Esta  es  la  primera  parte  de  un  trabajo  de  revisión  donde  se  reportan  los  conocimien-
tos actuales  del  retinoblastoma  (Rb)  y  sus  implicaciones  en  México  (incluyendo  la  experiencia
de los  autores  en  los  principales  centros  de  referencia),  así  como  las  brechas  en  la  práctica
y las  posibles  soluciones  para  mejorar  el  diagnóstico,  tratamiento  y  referencia  de  pacientes.
En esta  parte  se  resumen  los  conocimientos  generales  del  Rb,  su  diagnóstico  y  tratamiento.  Se
realizó una  revisión  de  los  avances  más  recientes  en  esta  enfermedad  publicados  en  PubMed  y
se resumieron  los  hallazgos  más  importantes.
La sospecha  oportuna  y  la  referencia  adecuada  de  pacientes  permiten  que  el  tratamiento
conservador  del  Rb  sea  curativo.  En  países  en  vías  de  desarrollo,  el  tratamiento  primario  es  el
salvamento  ocular  y  la  preservación  de  la  visión.  Las  opciones  de  quimioterapia  intraarterial  o
intravítrea permiten  ofrecer  opciones  terapéuticas  en  estos  pacientes.
Los avances  en  el  tratamiento  del  Rb  están  generalmente  limitados  a  países  industrializados.
Las implicaciones  de  los  hallazgos  de  esta  revisión  serán  discutidas  en  la  segunda  parte,  la  cual
será un  análisis  de  la  situación  de  los  programas  hospitalarios  del  Rb  en  México,  incluyendo  la
revisión de  los  datos  demográﬁcos  disponibles  de  los  centros  de  referencia  más  importantes.
© 2015  Hospital  Infantil  de  México  Federico  Gómez.  Publicado  por  Masson  Doyma  México
S.A. Este  es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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It  has  been  recently  discovered  that  ampliﬁcation  of  the. Introduction
etinoblastoma  (Rb)  is  the  most  common  primary  malig-
ancy  in  children,  most  frequently  occurring  in  children
5  years  of  age,  with  an  annual  incidence  ranging  worldwide
rom  36/1,000,000  live  births  to  67/1,000,000  live  births.1--5
ccurate  incident  rates  can  be  difﬁcult  to  estimate,  espe-
ially  in  developing  countries  that  lack  a  national  Rb  registry.
n  fact,  a  recent  study  from  the  Asia-Paciﬁc  region  would
uggest  that  cases  of  Rb  are  being  underreported  by  >50%.6
A  curable  cancer,  Rb  survival  rates  in  the  developed  world
ange  from  90-95%,  mainly  due  to  early  diagnosis  of  the  dis-
ase  and  to  the  advances  made  over  the  past  few  decades
n  conservative  treatment.5,7,8 However,  survival  rates  are
igniﬁcantly  lower  in  developing  countries;  in  Africa,  they
re  estimated  as  low  as  20%,  and  >3,000  annual  childhood
eaths  are  attributed  worldwide  to  Rb.8--10 The  poorer  out-
omes  in  developing  countries  have  been  associated  with
ate  diagnosis  and  treatment,  lower  educational  levels  of
he  mother,  lack  of  access  to  health  services,  and  treatment
bandonment  by  families  of  the  patient.11--13
This  article  is  the  ﬁrst  part  of  a  two-part  review  with
he  objective  to  report  the  current  situation  of  Rb  in  Mex-
co,  including  the  authors’  own  experience  at  the  country’s
eading  Rb  centers  and  a  review  of  currently  available
emographic  data  of  patients  with  Rb  at  hospitals  with  Rb
rograms  or  that  treat  for  Rb.  We  will  also  identify  gaps  in
ractice  and  propose  solutions  to  improve  diagnosis,  provide
dequate  treatment,  and  improve  patient  uptake.  The  situ-
tional  analysis  of  Rb  in  Mexico  will  be  performed  within  the
ontext  of  the  general  universal  knowledge  of  Rb  diagnosis
nd  management.  In  this  ﬁrst  part,  we  will  summarize  the
eneral  knowledge  of  Rb  diagnosis  and  management  includ-
ng  the  latest  advances  in  chemotherapy  options.
M
g
n. Methods
 general,  unstructured  literature  search  was  performed
sing  PubMed  to  search  for  peer-reviewed  journal  articles
n  the  current  knowledge  of  Rb  diagnosis  and  management.
o  speciﬁc  search  parameters  were  applied.  Key  ﬁndings
rom  the  literature  are  summarized.
. Results
.1.  Pathology,  diagnosis,  and  clinical
haracteristics
here  are  two  forms  of  Rb,  hereditary  or  non-hereditary,
oth  of  which  develop  from  the  mutation  of  the  Rb  (RB1)
ene.14--16 In  the  non-hereditary  form,  inactivation  of  the
B1  gene  alleles  causes  a  defect  of  the  pRB  protein,  result-
ng  in  unilateral  tumors.14,15 The  presence  of  tumors  in  both
yes  can  occur  with  heritable  Rb.15 A  parent  carrier  of  a  sin-
le  mutant  allele  of  the  RB1  gene  is  a hereditary  risk  factor
hat  predisposes  the  child  to  the  loss  of  the  second  copy  by
,000  times  the  rate  of  spontaneous  mutation.14 There
s  a  50%  chance  that  the  parent  passes  the  mutation  to
heir  child,  who  then  has  a  90%  chance  of  developing  Rb.17
he  hereditary  form  increases  the  risk  of  patient  suscep-
ibility  to  other  cancers  and  requires  long-term  follow-up,
enetic  counseling,  and  monitoring  for  second  cancers.15
he  genetic  nature  of  Rb,  therefore,  is  very  important  in
redicting  the  risk  of  cancer  and  guiding  treatment.YCN  gene  (found  only  in  tumor  cells)  results  in  another
enetic  form  of  the  disease.15,16 Patients  with  this  form  are
ot  at  risk  for  second  cancers.  However,  their  tumors  tend  to
edge
t
c
n
A
c
c
E
c
i
n
3
V
t
s
a
i
f
c
l
a
t
e
e
l
ﬁ
t
R
p
l
l
f
1
t
s
a
t
c
t
s
c
T
m
i
c
s
m
i
i
f
r
e
mRetinoblastoma  in  Mexico:  part  I.  A  review  of  general  knowl
be  larger,  invasive,  and  aggressive;  thus,  ocular  salvage  risks
high  morbidity  and  treatment  failure.  For  now,  enucleation
is  the  most  optimal  treatment  for  these  cases.15,18
Rb  is  generally  diagnosed  based  on  clinical  characteristics
at  presentation  that  are  found  using  imaging  modalities.5
Benign  lesions  and  end-stage  conditions  can  mimic  the  dis-
ease  and  lead  to  unnecessary  treatment;  thus,  careful  and
accurate  identiﬁcation  and  staging  of  the  disease  is  key  to
guiding  patient-based  treatment.19--23
Although  there  is  no  universal  staging  system  that  consid-
ers  all  risk  factors  of  the  disease  in  the  detection  process,
the  International  Classiﬁcation  for  Intraocular  Retinoblas-
toma  (ICIR)  has  been  validated  to  more  accurately  predict
treatment  outcomes.20--22 The  ICIR  stages  Rb  in  ﬁve  groups,  A
through  E,  with  Group  A  representing  more  easily  treatable
eyes  of  very  low  risk,  and  risk  progression  and  complex-
ity  of  treatment  increasing  through  Group  E,  the  very
high-risk  eyes.20 The  cancer  characteristics  of  each  ICIR
group  are  summarized  in  Table  1  with  the  recommended
treatments  and  their  associated  complications  and  risks.
Group  A  eyes  have  small  tumors  ≤3  mm  in  size,  lack  vit-
reous/subretinal  seeding,  and  are  located  ≥3  mm  from  the
foveola  and  ≥1.5  mm  from  the  optic  nerve.  Groups  B,  C,
and  D  eyes  have  tumors  of  any  size  or  location;  vitre-
ous/subretinal  seeding  becomes  present  in  Group  C  eyes,
whereas  Group  D  eyes  have  massive  seeds  and  retinal
attachment  can  occur.  Groups  A,  B,  and  C  can  be  man-
aged  conservatively  by  chemotherapy  with  the  objective
to  salvage  the  eye,  whereas  Group  D  requires  intra-arterial
chemotherapy  (IAC)  or  intravitreal  chemotherapy  (IVC).  For
Group  E  tumors  where  co-morbidities  such  as  irreversible
glaucoma  are  present,  the  tumor  approaches  the  lens  of  the
eye,  and  massive  intraocular  hemorrhage  is  present.  The
standard  of  care  is  enucleation,  although  IAC  may  also  be
used.
Histopathologic  evidence  of  high-risk,  metastatic  Rb
has  been  found  in  17%  of  Group  D  and  24%  of  Group  E
eyes,  indicating  that  even  after  enucleation,  adjunctive
chemotherapy  may  still  be  necessary  to  manage  the  spread
of  cancer  to  other  parts  of  the  body.39
3.2.  Rb  treatment  modalities:  conservative
management
Over  the  past  few  decades,  advances  in  genetic  technolo-
gies,  improved  staging  and  classiﬁcation,  and  a  multidis-
ciplinary  team  approach  to  conservative  management  of
Rb  have  transformed  the  treatment  primary  outcome  to
ocular  salvage  and  preservation  of  vision  in  Group  A,  B,
and  C  cases,  in  addition  to  many  advanced  cases  (Group
D).5,7,38,40--46 Systemic  chemotherapy  is  commonly  used  to
treat  the  tumor  with  ocular  salvage  rates  of  30-90%.45,47
Other  conservative  modalities  are  focal  consolidation  and
transpupillary  thermotherapy  (TTT),  laser  photocoagula-
tion  (LP),  cryotherapy  (CT),  plaque  brachytherapy,  and
local  chemotherapy  delivered  by  subconjunctival,  subtenon,
intravitreal,  or  intra-arterial  routes  (Table  1).  Combined
conservative  treatment  has  been  proven  to  be  more  effec-
tive,  in  which  chemotherapy  is  initially  applied  to  reduce
the  tumor  size  so  that  local  therapies  such  as  CT  or  TTT
can  then  eliminate  the  disease.5 Choosing  which  modalities
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o  use  depends  on  the  patient  and  tumor  stage,  and  the
omplications  and  risks  vary  (Table  1).
In  the  more  advanced  cases  (Groups  E  and  D),  exter-
al  beam  radiotherapy  (EBRT)  and  enucleation  are  applied.
 10-year  retrospective  review  of  the  use  of  systemic
hemotherapy  in  Sweden  at  the  sole  national  Rb  referral
enter  found  that  35%  of  all  eyes  required  enucleation  and
BRT,  as  well  as  91%  of  eyes  with  Group  C/D  tumors.46 Enu-
leation  is  the  standard  of  care  for  when  sight  preservation
s  very  unlikely  or  where  the  tumor  may  spread  to  the  optic
erve,  choroid,  or  orbit.5,38
.3.  Advanced  therapy  for  Rb:  IAC  and  IVC
itreous  seeding  is  the  main  barrier  to  successful  conserva-
ive  treatment  of  advanced  Rb.48 Chemoresistant  vitreous
eeds  form  in  tumor  cells  after  the  cells  proliferate  in  the
vascular  vitreous  environment.  IAC  and  IVC  are  emerg-
ng  primary  therapies  to  prevent  EBRT  or  enucleation
or  advanced  cases  with  vitreous  seeding  in  developed
ountries.48--52 IAC  with  melphalan/topotecan  is  now  a  ﬁrst-
ine  treatment  for  Group  C  and  D  eyes.52,53 The  goal  is  to
chieve  tumor  regression  with  minimal  local  and  systemic
oxicities.  Evidence  is,  however,  limited  on  the  safety  and
fﬁcacy  of  IAC.54
Multiple  preclinical  and  clinical  studies  in  Argentina  have
valuated  the  safety  and  efﬁcacy  of  intra-arterial  melpha-
an  and  topotecan.55--57 Schaiquevich  et  al.  reported  the
rst  pharmacokinetic  study  of  melphalan  after  superselec-
ive  ophthalmic  artery  infusion  (SSOAI)  in  children  with
b,  in  addition  to  evaluating  and  validating  the  effect  in
igs.55 The  authors  evaluated  the  cytotoxicity  of  melpha-
an  administered  with  and  without  topotecan  in  Rb  cell
ines  of  17  patients  and  ﬁve  pigs.  The  authors  previously
ound  that  topotecan  permeated  more  efﬁciently  by  5-  to
0-fold  into  the  vitreous  cavity  of  the  same  animal  model
han  melphalan.58 Plasma  concentration  vs.  time  proﬁle  was
imilar  when  corrected  by  weight  in  both  patients  and  the
nimal  model.55 There  was  thus  a  low  systemic  exposure
o  melphalan  in  the  patients.  At  4  h  post-SSOAI,  topotecan
oncentrations  in  the  vitreous  of  the  pigs  remained  greater
han  its  IC50;  a  similar  effect  was  not  found  in  pigs  treated
olely  with  melphalan,  which  appears  to  permeate  inefﬁ-
iently  through  the  blood-retinal  barrier  to  the  vitreous.55,58
he  authors  suggested  that  a  SSOAI  combined  regimen  of
elphalan  and  topotecan  might  be  a  safer  alternative  to
ncreasing  melphalan  dosage.55 These  ﬁndings  were  further
onﬁrmed  by  the  authors  in  a  single-center,  prospective
tudy  that  evaluated  the  safety  and  efﬁcacy  of  combined
elphalan  (3-6  mg)  and  topotecan  (0.5-1)  for  66  cycles  SSOAI
n  26  patients  (27  eyes)  with  Rb.56 This  regimen  was  admin-
stered  as  primary  therapy  in  ﬁve  eyes,  which  all  responded
avorably  and  were  preserved.  In  22  eyes  with  relapsed  or
esistant  tumors,  16  responded  well,  whereas  three  were
nucleated  after  a  median  of  8  months  (range:  7.9-9.1
onths).  Grade  III  and  IV  neutropenia  had  respective  inci-
ence  rates  of  10.6%  and  1.5%,  without  any  fever.  Blood
ransfusion  was  not  required,  which  further  demonstrated
 hematologic  toxicity  proﬁle  comparable  with  single-agent
elphalan.56
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Table  1  Treatment  modalities  for  the  conservative  management  of  retinoblastoma  based  on  the  International  Classiﬁcation
for Intraocular  Retinoblastoma  (ICIR)20
ICIR  Group20 Characteristics20 Treatment  Recommended24 Complications/Risks
A  (very  low  risk)  •  Tumors  ≤3  mm  in  size
• Tumors  found  ≥3  mm  from
the  foveola  and  ≥1.5  mm  from
the optic  nerve
•  No  vitreous/subretinal
seeding
Focal  therapy  including:
•  Transpupillary
thermotherapy  (TTT)
• Cryotherapy  (CT)
•  Laser  photocoagulation
(LP)
Complications  vary  for  each
therapy:
• TTT:  Focal  iris  atrophy  and
peripheral  focal  lens  opacity25
•  CT:  lid  edema,  transient
conjunctival  edema,  and  transient
localized  serous  retinal
detachments26,27
•  LP:  retinal  detachment,  vascular
occlusions,  retinal  traction,
and pre-retinal  ﬁbrosis28--30
B  (low  risk)  •  Tumors  of  any  size/location
•  No  vitreous/subretinal
seeding
•  Subretinal  ﬂuid  cuff
extending  ≤5  mm  from  the
tumor  base
•  Systemic  chemotherapy
(VEC)
•  Focal  therapy  with
chemotherapy  cycles
• Plaque  radiotherapy  (PRT)
C (moderate  risk)  •  Discrete  tumors  of  any
size/location
•  Focal  vitreous/subretinal
seeding  present  that  extends
≤3  mm  from  tumor  base
• ≤1  quadrant  of  subretinal
ﬂuid  may  be  present
•  Systemic  chemotherapy
(VEC)
•  Focal  therapy
• Subtenon  carboplatin
(STC)
•  PRT:  dryness  of  the  eye,
irritation,  madarosis,  cataract,
scleral  necrosis,  radiation
retinopathy  or  papillopathy,  optic
neuropathy,  and  strabismus31--34
•  STC:  optic  nerve  ischemic
necrosis/atrophy,  reduced  ocular
motility,  moderate  loss  of  orbital
volume,  and  pseudopreseptal
cellulitis35--37
•  EBRT:  vision  loss,  cataracts,
irritation5
D  (high  risk)  •  Diffuse  vitreous  subretinal
seeding  and/or  massive
nondiscrete
endophytic/exophytic  disease
present
• ≥1  quadrant  of  retinal
detachment
•  Systemic  chemotherapy
(VEC)
•  Focal  therapy
• STC
• EBRT
E (very  high  risk)  One  or  more  of  the  following
present  in  eyes:
•  Irreversible  neovascular
glaucoma
•  Massive  intraocular
hemorrhage
•  Aseptic  orbital  cellulitis
• Phthisis/pre-phthisis  tumor
anterior  to  anterior  vitreous
face
•  Tumor  touches  the  lens
Diffuse  inﬁltrating
retinoblastoma
•  EBRT5
•  Enucleation38
 28 d
c
s
iVEC, vincristine, etoposide, carboplatin via six cycles given everyThe  same  authors  next  evaluated  the  effect  of  SSOAI
ompared  to  a  historical  cohort  of  sequential  periocular  and
ystemic  chemotherapy  on  ocular  salvage  for  18  patient  eyes
n  15  consecutive  patients  that  failed  chemoreduction  and
E
S
c
eays; EBRT, external beam radiotherapy.BRT  in  a  pilot  program.57 Three  eyes  were  treated  with
SOAI  using  melphalan  alone,  four  eyes  were  treated  with
ombined  topotecan,  carboplatin,  and  melphalan,  and  one
ye  was  treated  with  topotecan  and  carboplatin  without
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melphalan;  all  eyes  received  a  median  of  four  cycles  of  SSOAI
(range:  2-9).  Periocular  topotecan  or  carboplatin  was  admin-
istered,  respectively,  to  nine  and  one  eyes  in  a  median  of
two  cycles  (range:  1-3)  followed  by  intravenous  topotecan
and  cyclophosphamide.  All  patients  survived  their  treatment
without  extraocular  dissemination  or  second  malignancy  and
with  similar,  mild  ocular  toxicity.  Enucleation-free  eye  sur-
vival  at  12  months  had  a  probability  of  0.87  (95%  conﬁdence
interval  [CI]:  0.42-0.97)  for  the  SSOAI  group  compared  to  0.1
(95%  CI:  0.06-0.35)  for  the  periocular  group  (p  <0.01).  Sys-
temic  toxicity  was  low  for  both  groups;  however,  patients
treated  with  intravenous  chemotherapy  had  ﬁve  episodes  of
grade  4 neutropenia,  three  of  which  required  hospitaliza-
tions,  whereas  no  such  complications  occurred  in  the  SSOAI
group.  Thus,  SSOAI  was  signiﬁcantly  superior  and  less  toxic
when  compared  to  periocular  and  systemic  chemotherapy  in
eyes  with  relapsed  Rb.57
Outside  of  Argentina,  a  systematic  review  on  the  compli-
cation  of  IAC  found  that  signiﬁcant  complications  were
uncommon  and  supports  that  the  risk  may  be  minimized
through  careful  injection  and  limiting  the  dosage.59 A  more
recent  retrospective  interventional  case  series  found  that
IAC  was  an  effective  primary  and  secondary  treatment  with
a  mean  globe  salvage  rate  for  Group  A-D  eyes  of  95%  and  a
salvage  rate  of  36%  for  Group  E  eyes.60 The  authors  observed
that  treatment  failed  in  eyes  with  extensive  recurrent  vitre-
ous  seeds.  It  should  be  taken  into  consideration  that  vascular
toxic  effects  in  the  eye  and  orbit  have  recently  been  demon-
strated  in  primates  after  IAC.61 Further  research  is  necessary
to  conﬁrm  and  validate  that  IAC  is  safe  and  effective,  includ-
ing  a  multi-center,  prospective  trial  that  would  analyze  the
globe  salvage  beneﬁts  of  IAC,48,59 but  IAC  appears  to  be
appropriate  treatment  for  a  select  patient  population  with
Rb.62
An  alternative  therapy  for  tumors  with  vitreous  seeds,
IVC  is  a  regimen  of  high-dosage  chemotherapy  and  has  an
ocular  salvage  rate  of  71-95%  and  a  vision  salvage  rate  of
9%  (among  patients  with  ocular  salvage).63 The  presence  of
vitreous  seeding  reduces  the  prognosis  of  tumor  control.  IVC
o
c
a
d
Table  2  A  summary  of  key  ﬁndings  on  the  current  knowledge  of  
•  Retinoblastoma  is  the  most  common  primary  malignancy  in  child
per 1  million  live  births.
• The  International  Classiﬁcation  for  Intraocular  Retinoblastoma  ha
outcomes and  uses  staging  based  on  ﬁve  groups  (Groups  A-E),  wi
low risk  and  Group  E  representing  very  high-risk  eyes  requiring  t
• Early  detection  of  retinoblastoma  in  Group  A  through  C  eyes  is  e
the patient  without  risking  vision  loss.
• Ocular  salvage  and  sight  preservation  are  the  primary  treatment
and many  Group  D  eyes.
• External  beam  radiotherapy  and  enucleation  are  indicated  for  Gr
sight preservation  is  unlikely  and  the  tumor  may  spread  to  the  o
• Intra-arterial  chemotherapy  with  melphalan/topotecan  is  now  a  
• Chemoresistant  vitreous  seeds  that  form  in  tumor  cells  after  they
treatment  of  advanced  retinoblastoma.
• Intravitreal  chemotherapy  using  melphalan  and/or  topotecan  is  a
seeds. However,  higher  doses  of  melphalan  risk  compromised  ret
and shows  minimal  ocular  toxicity. of  the  disease  303
ith  melphalan  offers  an  option  for  these  patients.  It  has
o  be  done  by  an  experienced  group  because  of  eligibility
riteria  and  the  high  risk  of  tumor  spread,  in  addition  to
he  risk  of  retinal  detachment  following  repeated  intravit-
eal  applications.58 Francis  et  al.  caution  using  a  dosage  of
30  mg  of  intravitreal  melphalan  when  vitreous  seeds  are
resent,  as  IVC  using  melphalan  resulted  in  compromised
etinal  function  in  their  combined  clinical  and  animal  study
f  16  patients  eye  and  12  rabbit  eyes.64 However,  if  the  seeds
re  not  injected  with  melphalan  and  cryotherapy  is  applied
mmediately  at  the  site,  risks  can  be  minimal.65
For  example,  other  recent  animal  and  clinical  stud-
es  in  Argentina  have  evaluated  the  safety  and  efﬁcacy
f  IVC  using  topotecan58,66,67 and  digoxin68 with  promising
esults.  As  an  alternative  to  melphalan,  intravitreal  injec-
ions  of  5  g of  topotecan  were  administered  to  rabbits.58
or  up  to  48  h  following  administration,  high  concentra-
ions  of  topotecan  were  observed  in  the  vitreous  humor,
ith  the  respective  median  maximum  vitreous,  aqueous,
nd  plasma  total  topotecan  concentrations  being  5.3,  0.68,
nd  0.21  g/ml.  There  was  evidence  of  low  systemic  expo-
ure  with  total  topotecan  exposure  in  the  vitreous  50  times
reater  than  the  total  systemic  exposure.  Next,  the  authors
ested  two  different  doses  of  5  g  vs.  0.5  g  of  intravitreal
opotecan  administered  to  rabbits  in  4  weekly  injections  to
ee  if  a  lower  dose  had  a  potential  therapeutic  effect.66
yes  injected  with  either  dose  demonstrated  no  signiﬁ-
ant  differences  in  electroretinography  wave  amplitudes
nd  implicit  times  in  comparison  in  compared  with  a  control
roup  (p  >  0.05).  There  was  no  signiﬁcant  histologic  dam-
ge  of  the  retinas  in  rabbits  treated  with  topotecan  and  no
ther  complications  observed.  Although  4  weekly  intravit-
eal  injections  of  5  g  or  0.5  g  of  topotecan  were  safe  in
he  rabbits’  eye,  lactone  topotecan  vitreous  concentrations
n  rabbits  injected  with  only  0.5  g  were  potentially  active
66nly  after  5  h. The  same  authors  reviewed  42  animal  and
linical  studies  for  the  ocular  pharmacology  and  antitumor
ctivity  of  topotecan  and  campothecins  for  Rb  treatment  via
ifferent  administrative  methods.67 Topotecan  administered
retinoblastoma.
ren,  with  a  global  incidence  ranging  from  36  to  67
s  been  validated  to  accurately  predict  treatment
th  Group  A  representing  more  easily  treated  eyes  with  very
he  most  complex  therapy.
ssential  for  a  timely  referral  to  treat  and  potentially  cure
 outcomes  following  systemic  chemotherapy  of  Group  A-C
oup  D  and  Group  E  eyes,  with  enucleation  necessary  when
ptic  nerve,  choroid,  or  orbit.
ﬁrst-line  treatment  for  Group  C  or  D  eyes.
 proliferate  are  the  main  barrier  to  successful  conservative
 therapeutic  option  for  advanced  tumors  with  vitreous
inal  function,  whereas  up  to  5  g  of  topotecan  is  effective
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104  
lone  or  combination  via  IAC  and  IVC  was  effective  with
inimal  ocular  toxicity.  However,  its  clinical  role  and
ptimal  dose  and  route  of  administration  remain  to  be
etermined.67
. Discussion
his  ﬁrst  review  of  our  two-part  study  has  its  limitations,  as
t  is  meant  to  be  a  general  overview  of  the  current  advances
n  Rb  diagnosis  and  management.  It  by  no  means  employs  a
igorous  or  systematic  methodology.  Part  1  serves  as  the  back
rop  and  context  of  the  current  situation  of  Rb  knowledge
nd  programming  in  Mexico,  which  will  be  explored  in  Part  2.
The  key  ﬁndings  for  this  review  of  recent  literature  on  the
eneral  knowledge  and  advances  of  Rb  diagnosis  and  man-
gement  are  summarized  in  Table  2.  Today,  provided  there
s  early  detection  and  referral  of  patients  with  Rb,  this  most
ommonly  occurring  pediatric  cancer  is  curable.  In  devel-
ped  countries,  the  primary  treatment  outcome  is  ocular
alvage  with  sight  preservation.  Advanced  chemotherapeu-
ic  options  such  as  IAC  and  IVC  can  now  save  even  the  most
dvanced  tumors.
Unfortunately,  there  are  gaps  in  practice  and  skill  in  con-
ervative  management  in  lesser  developed  countries  where
b  is  often  diagnosed  after  metastasis  has  occurred.10,47,69--71
n  upper-middle  income  countries,  large  urban  centers  may
ave  the  latest  technology  and  skilled  highly  specialized
edical  professionals,  but  these  services  are  often  not
ccessible  to  the  population  living  outside  these  urban
reas.69,71 This  is  the  case  in  Argentina,  an  upper-middle
ncome  country  where  more  proliﬁc,  advanced  research  on
b  has  been  done  in  recent  years.55--58,64,66--68 Yet,  children
iving  outside  of  the  capital  city  of  Buenos  Aires  have  a  sig-
iﬁcantly  higher  risk  of  having  Rb.71
In  Part  2  of  this  study,  we  will  examine  the  literature
elated  to  Rb  in  another  upper-middle  income  country,  Mex-
co,  and  compare  it  to  the  general  knowledge  presented
ere  in  Part  1,  analyze  the  state  of  Rb  programming  in  the
ountry,  and  report  the  patient  data  currently  available  at
ospitals  in  Mexico  that  have  formal  Rb  programs  or  treat
atients  with  Rb.
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